Apac Point Care Testing Poct Market
Размер рынка в млрд долларов США
CAGR : %
Прогнозируемый период |
2022 –2029 |
Размер рынка (базовый год) |
USD 29.00 Billion |
Размер рынка (прогнозируемый год) |
USD 64.46 Billion |
CAGR |
|
Основные игроки рынка |
|
>Asia-Pacific Point-of-Care Testing (POCT) Market, By Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies) – Industry Trends and Forecast to 2029
Market Analysis and Size
Point-of-care testing, which is defined as testing that may be done in close proximity to the patient and allows a medical choice to be taken right away based on the results and monitoring. point-of-care testing (POCT), also known as with-patient testing, allows doctors to assess accurate real-time, lab-quality diagnostic results in minutes rather than hours. It guarantees that patients get the most effective and efficient care possible, whenever and wherever they need it.
Data Bridge Market Research analyses that the point-of-care testing (POCT) market which was USD 29 billion in 2021, would rocket up to USD 64.46 billion by 2029, and is expected to undergo a CAGR of 10.5% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
POC tests are not as highly preferred as central laboratory tests because of low volume and high cost. This puts additional strain on the billing system, which must give distinct codes for POC tests. This might result in billing errors by inexperienced or newly hired employees, as well as failure to enter data into the data management system due to mismatched test codes.
Report Scope and Market Segmentation
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2014 - 2019) |
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
Segments Covered |
Продукт (продукты для мониторинга глюкозы, продукты для кардиометаболического тестирования, продукты для тестирования на инфекционные заболевания, продукты для тестирования на беременность и фертильность, продукты для тестирования на маркеры опухолей/рака, продукты для анализа мочи, продукты для тестирования на холестерин, продукты для гематологического тестирования, продукты для тестирования на наркотики, продукты для тестирования на скрытую кровь в кале, быстрые тесты на коагуляцию и другие продукты POC), Применение (переливание крови, мониторинг сердца, коагуляция, уровень глюкозы в крови, гематология , неинвазивный мониторинг SPO2, неинвазивный мониторинг PCO2, анализ цельной крови, мониторинг основных показателей жизнедеятельности и другие), Платформа (анализы бокового потока/иммунохроматографические тесты, тест-полоски, микрофлюидика, молекулярная диагностика и иммуноанализы), Режим назначения (тестирование по рецепту и безрецептурное тестирование), Тип тестирования (иммуноанализы, Клеточные анализы, амплификация нуклеиновых кислот, клинические биохимические анализы и гематология), конечный пользователь (больницы, клиники, лаборатории, учреждения по уходу на дому, центры амбулаторной хирургии и другие), канал сбыта (прямые тендеры и розничные аптеки) |
Страны, охваченные |
Китай, Япония, Индия, Южная Корея, Сингапур, Малайзия, Австралия, Таиланд, Индонезия, Филиппины, Остальные страны Азиатско-Тихоокеанского региона (APAC) в Азиатско-Тихоокеанском регионе (APAC) |
Охваченные участники рынка |
Abbott (США), F. Hoffmann-La Roche Ltd (Швейцария), BD (США), Siemens Healthcare Private Limited (Германия), Bio-Rad Laboratories, Inc. (США), Danaher (США), Sekisui Diagnostics (США), Trinity Biotech (Ирландия), bioMérieux (Франция), EKF Diagnostics (Германия), AccuBioTech Co., Ltd. (Китай), Instrumentation Laboratory (США), Beckman Coulter, Inc. (США), PTS Diagnostics (США), Nova Biomedical (США), Chembio Diagnostics, Inc. (США), Quidel Corporation (США) и Sienco, Inc (США) |
Возможности рынка |
|
Динамика рынка тестирования в местах оказания медицинской помощи (POCT)
Драйверы
- Тенденция к росту распространенности заболеваний в развивающихся странах
В развивающихся странах растет число хронических заболеваний и острых инфекций, что обусловлено, среди прочего, неосведомленностью о здоровье, плохой медицинской инфраструктурой и малоподвижным образом жизни. В результате этих обстоятельств диагностика и лечение задерживаются, как и качество получаемой помощи. Потребность в тестах для быстрой диагностики в месте оказания помощи растет из-за их удобства использования, экономической эффективности и небольшого размера продукта.
- Преимущества, связанные с безрецептурным тестом
Ожидается, что рынок тестирования на месте оказания медицинской помощи для тестов TC будет развиваться на 7,1% CAGR до 2027 года из-за увеличения количества безрецептурных тестов, таких как тесты на беременность и тесты на уровень глюкозы в крови, которые дают результаты за считанные секунды. Эти обследования не требуют привлечения квалифицированного специалиста и могут проводиться самими людьми, продвигая отрасль вперед. Например, набор First Response представляет собой быстрый тест на беременность, который дает ответ за 60 секунд. Наборы для измерения уровня глюкозы в крови Accu-Chek Active также предоставляют клиентам показания за 5 секунд, что повышает спрос на рынке.
- Рост заболеваемости диабетом и ожирением приводит к сердечно-сосудистым заболеваниям
В связи с возросшей распространенностью диабета и ожирения прогнозируется, что рынок тестирования на кардиометаболические показатели в пунктах оказания медицинской помощи к 2027 году превысит 5,3 млрд долларов США. Кардиометаболический тест также определяет процентный уровень докозагексаеновой кислоты (ДГК) и эйкозапентановой кислоты (ЭПК) в мембране эритроцитов. Это также помогает выявлять новые факторы риска остановки сердца и других заболеваний, связанных с сердцем.
Возможности
- Технологический прогресс в области анализа латерального потока
Ожидается, что рынок латеральных проточных анализов в точках оказания помощи достигнет 11,8 млрд долларов США к 2027 году. Росту отрасли будет способствовать запуск новых продуктов, которые позволят быстро продвигаться в исследованиях и разработках (НИОКР) диагностических инструментов для точек оказания помощи (POCT). Кроме того, достижения в области материалов компонентов, технологий считывания, реагентов и повышение чувствительности сделали количественные результаты более возможными при использовании латерального проточного анализа, поддерживая рост сектора.
Ограничения/Проблемы
- Строгая регуляторная политика
Из-за жестких и трудоемких нормативных требований отрасль тестирования в местах оказания медицинской помощи растет медленно. С расширением сферы использования и ростом внедрения в развивающихся экономиках регулирующие органы уделяют больше внимания соблюдению требований, безопасности и удобству использования тестирования в местах оказания медицинской помощи (POCT). Тестирование в местах оказания медицинской помощи классифицируется Управлением по контролю за продуктами и лекарствами США как медицинские устройства класса II. Эти устройства обеспечивают разумную гарантию эффективности и безопасности устройства.
- Отсутствие соответствия окончательным методам центральной лаборатории
Неподходящие показания для проведения теста, неподходящее время и методы взятия проб, отсутствие информации о состоянии пациента и другие факторы, такие как голодание перед функциональными тестами или изменения позы/позы во время аналогичных тестов, — все это примеры преаналитических ошибок при тестировании POC.
В этом отчете о рынке тестирования в точках оказания медицинской помощи (POCT) содержатся сведения о последних новых разработках, правилах торговли, анализе импорта-экспорта, анализе производства, оптимизации цепочки создания стоимости, доле рынка, влиянии внутренних и локальных игроков рынка, анализируются возможности с точки зрения новых источников дохода, изменений в правилах рынка, анализ стратегического роста рынка, размер рынка, рост рынка категорий, ниши приложений и доминирование, одобрения продуктов, запуски продуктов, географические расширения, технологические инновации на рынке. Чтобы получить больше информации о рынке тестирования в точках оказания медицинской помощи (POCT), свяжитесь с Data Bridge Market Research для получения аналитического обзора, наша команда поможет вам принять обоснованное рыночное решение для достижения роста рынка.
Влияние COVID-19 на рынок тестирования в местах оказания медицинской помощи (POCT)
Растущее использование тестов на месте оказания помощи, которые могут быстро идентифицировать COVID-19, рынок диагностики на месте оказания помощи значительно вырастет в 2022 году. Тестирование на месте оказания помощи стало важным диагностическим методом из-за необходимости быстрых диагностических результатов. Наборы для быстрого тестирования антигенов, которые можно эффективно использовать в условиях места оказания помощи, пользуются большим спросом из-за быстро растущего числа случаев COVID-19 и растущего давления на правительства с целью улучшения управления пациентами. Различные существенные причины, которые, как прогнозируется, будут способствовать долгосрочному росту рынка диагностики на месте оказания помощи, включают растущую распространенность других респираторных заболеваний во всем мире, переход к децентрализованной диагностике и расширенный доступ к устройствам на месте оказания помощи через онлайн-платформы.
Недавнее развитие
Компания Roche представила свою систему Cobas Pulse в ряде стран, имеющих маркировку CE, в январе 2022 года. Это новейшее поколение решений Roche Diagnostics для профессионального контроля уровня глюкозы в крови в местах оказания медицинской помощи.
В октябре 2021 года компания Thermo Fisher Scientific объявила о получении разрешения FDA на экстренное использование (EUA) для проведения тестов на COVID-19 с использованием устройства для сбора данных SpectrumDNA SDNA-1000 компании Spectrum Solutions — высокопроизводительной автоматизированной системы тестирования COVID-19 на базе Amplitude Solution с использованием нового метода сбора образцов слюны.
Система SPECIFIC REVEAL Rapid AST была совместно эксклюзивно распространена в Европе компаниями bioMérieux и Specific Diagnostics в июне 2021 года. Система работает в тандеме с BIOFIRE BCID2 компании bioMérieux.
Масштаб рынка тестирования в местах оказания медицинской помощи (POCT) в Азиатско-Тихоокеанском регионе
Рынок тестирования в точке оказания медицинской помощи (POCT) сегментирован на основе продукта, технологии, рецепта, применения, конечного пользователя и канала сбыта. Рост среди этих сегментов поможет вам проанализировать сегменты с незначительным ростом в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи, которые помогут им принимать стратегические решения для определения основных рыночных приложений.
Продукт
- Мониторинг уровня глюкозы
- Полоски
- Счетчики
- Ланцеты
- Кардиометаболическое тестирование
- Тестирование сердечных маркеров
- hsTnl
- БНП
- D-димер
- CK-MB
- Миоглобин
- Другие
- Анализ газов крови/электролитов
- Тестирование HBA1C
- Infectious disease testing
- Influenza testing
- HIV testing
- Hepatitis C testing
- Sexually Transmitted Disease (STD) testing
- Healthcare-Associated Infection (HAI) testing
- Respiratory infection testing
- Tropical disease testing
- Other infectious diseases testing
- Coagulation testing
- PT/INR testing
- Activated Clotting Time (ACT/APTT) testing
- Pregnancy and fertility testing
- Pregnancy testing
- Fertility testing
- Tumor/Cancer marker testing
- Urinalysis testing
- Cholesterol testing
- Hematology testing
- Drugs-of-abuse testing
- Fecal occult testing
- Others
Technology
- Lateral flow assays
- Dipsticks
- Microfluidics
- Molecular diagnostics
- Immunoassays
- Agglutination assays
- Flow-through
- Solid phase
- Biosensors
Prescription
- OTC testing
- Prescription-based testing
Application
- Cardio metabolic testing
- Infectious disease testing
- Nephrology testing
- Drug-of-Abuse (DoA) testing
- Blood glucose testing
- Pregnancy testing
- Cancer biomarker testing
- Other applications
End-user
- Hospitals
- Diagnostic centers
- Research laboratories
- Home-care settings
- Others
Distribution Channel
- Direct tender
- Retail Pharmacies
Point-of-Care Testing (POCT) Market Regional Analysis/Insights
The point-of-care testing (POCT) market is analysed and market size insights and trends are provided by country, product, technology, prescription, application end-user and distribution channel as referenced above.
The countries covered in the point-of-care testing (POCT) market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China is expected to dominate the market because point-of-care testing (POCT) products in China have a massive application space in the fields of hospital operation, emergency department, intensive care, chronic disease prevention and control, public health emergencies, county-level medical institution construction, and new rural supportive medical care.
Japan will dominate the market due to an increasing number of people suffering from HIV and other illnesses, which will result in a high approval rate for point-of-care testing devices in the country. India is the dominant country due to the high prevalence of diseases among its people.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The point-of-care testing (POCT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for point-of-care testing (POCT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the point-of-care testing (POCT) market. The data is available for historic period 2010-2020.
Competitive Landscape and Point-of-Care Testing (POCT) Market Share Analysis
The point-of-care testing (POCT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to point-of-care testing (POCT) market.
Some of the major players operating in the point-of-care testing (POCT) market are:
- Abbott (U.S)
- F. Hoffmann-La Roche Ltd (Switzerland)
- BD (U.S)
- Siemens Healthcare Private Limited (Germany)
- Bio-Rad Laboratories, Inc. (U.S)
- Danaher (U.S)
- Sekisui Diagnostics (U.S)
- Trinity Biotech (Ireland)
- bioMérieux (France)
- EKF Diagnostics (Germany)
- AccuBioTech Co., Ltd. (China)
- Instrumentation Laboratory (U.S)
- Beckman Coulter, Inc. (U.S)
- PTS Diagnostics (U.S)
- Nova Biomedical (U.S)
- Chembio Diagnostics, Inc. (U.S)
- Quidel Corporation (U.S)
- Sienco, Inc (U.S)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 LIST OF DISTRIBUTORS IN ASIA PACIFIC REGION FOR POINT-OF-CARE-TESTING MARKET
5 COVID-19 IMPACT ON ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
5.1 IMPACT ON DEMAND
5.2 PRICE IMPACT
5.3 IMPACT ON SUPPLY CHAIN
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS
5.5 CONCLUSION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 GROWING POPULARITY OF WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES
6.1.4 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING
6.3.3 TECHNOLOGICAL ADVANCEMENTS IN POINT-OF-CARE TESTING DEVICES
6.4 CHALLENGE
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.1.1 GLUCOSE MONITORING PRODUCTS
7.1.1.1 STRIPS
7.1.1.2 METERS
7.1.1.3 LANCETS & LANCING DEVICES
7.1.2 INFECTIOUS DISEASE TESTING PRODUCTS
7.1.2.1 INFLUENZA
7.1.2.2 HIV TESTING PRODUCTS
7.1.2.3 HEPATITIS C
7.1.2.4 SEXUALLY TRANSMITTED DISEASE (STD)
7.1.2.5 HEALTHCARE-ASSOCIATED INFECTION (HAI)
7.1.2.6 RESPIRATORY INFECTION
7.1.2.7 TROPICAL DISEASE
7.1.2.8 OTHER INFECTIOUS DISEASE
7.1.3 CARDIOMETABOLIC TESTING PRODUCTS
7.1.3.1 BLOOD GAS/ELECTROLYTES
7.1.3.2 HBA1C TESTING PRODUCTS
7.1.3.3 CARDIAC MARKER TESTING PRODUCTS
7.1.3.4 LIPID TESTING KITS
7.1.4 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.1.4.1 PREGNANCY TESTING PRODUCTS
7.1.4.2 FERTILITY TESTING PRODUCTS
7.1.5 HEMATOLOGY TESTING PRODUCTS
7.1.5.1 BLOOD ANAYZER
7.1.5.2 REAGENTS AND KITS
7.1.6 RAPID COAGULATION TESTING
7.1.6.1 COAGULATION ANALYZER
7.1.6.2 TESTING KIT
7.2 DRUGS-OF-ABUSE TESTING PRODUCTS
7.3 URINALYSIS TESTING PRODUCTS
7.4 CHOLESTEROL TESTING PRODUCTS
7.5 TUMOR/CANCER MARKER TESTING PRODUCTS
7.6 FECAL OCCULT TESTING PRODUCTS
7.7 OTHER POC PRODUCTS
8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 BLOOD GLUCOSE
8.3 CARDIAC MONITORING LUCOSE
8.4 HAEMATOLOGY
8.4.1 WBC COUNT
8.4.2 DNA SEQUENCING REAGENTS & KITS
8.5 COAGULATION
8.6 WHOLE BLOOD ANALYSIS
8.6.1 BLOOD GASES
8.6.2 ELECTROLYTES & METABOLITES
8.7 VITAL SIGN MONITORING
8.7.1 HEART RATE
8.7.2 BLOOD PRESSURE
8.7.3 RESPIRATORY RATE 59.37
8.7.4 TEMPERATURE
8.8 NON- INVASIVE SPO2 MONITORING
8.9 NON- INVASIVE PCO2 MONITORING
8.1 BLOOD TRANSFUSION
9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM
9.1 OVERVIEW
9.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS
9.3 DIPSTICKS
9.4 MOLECULAR DIAGNOSTICS ENOME SEQUENCING
9.5 IMMUNOASSAYS
9.6 MICROFLUIDICS
10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE
10.1 OVERVIEW
10.2 OTC TESTING
10.3 PRESCRIPTION-BASED TESTING
11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE
11.1 OVERVIEW
11.2 IMMUNOASSAYS
11.3 NUCLEIC ACID AMPLIFICATION TESTING
11.4 HAEMATOLOGY
11.5 CLINICAL CHEMISTRY ASSAYS
11.6 CELL-BASED ASSAYS
12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER
12.1 OVERVIEW
12.2 CLINICS
12.3 HOME CARE
12.4 HOSPITALS
12.5 LABORATORIES
12.6 AMBULATORY SURGICAN CENTERS
12.7 OTHERS
13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL PHARMACIES
14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET BY COUNTRY
14.1 OVERVIEW
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 THAILAND
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F.HOFFMANN-LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHCARE PRIVATE LIMITED
17.2.1 COMPANY SNAPSHOT
17.2.1 PRODUCT PORTFOLIO
17.2.2 RECENT DEVELOPMENTS
17.3 BD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.4 DANAHER
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENTS
17.5 BIOMÉRIEUX SA
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ACCUBIOTECH CO.,LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 BECKMAN COULTER,INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BIO-RAD LABORATORIES, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CHEMBIO DIAGNOSTICS SYSTEMS,INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 EKF DIAGNOSTICS
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 INSTRUMENTATION LABORATORY
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 NOVA BIOMEDICAL
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PTS DIAGNOSTICS
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 QUIDEL CORPORATION
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 SEKISUI DIAGNOSTICS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SIENCO,INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TRINITY BIOTECH
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Список таблиц
LIST OF TABLES
TABLE 1 DIFFERENT ASSOCIATIONS FOR DIAGNOSTICS
TABLE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 3 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 4 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 5 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 6 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 21 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 36 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 37 CHINA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 38 CHINA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 39 CHINA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 40 CHINA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 41 CHINA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 42 CHINA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 43 CHINA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 44 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 45 CHINA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 46 CHINA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 47 CHINA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 48 CHINA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 49 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 50 CHINA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 51 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 52 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 53 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 54 JAPAN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 55 JAPAN CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 56 JAPAN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 57 JAPAN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 58 JAPAN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 59 JAPAN HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 60 JAPAN RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 61 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 62 JAPAN HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 JAPAN WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 64 JAPAN VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 65 JAPAN POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 66 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 67 JAPAN POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 68 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 69 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 70 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 71 INDIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 72 INDIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 73 INDIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 74 INDIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 75 INDIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 76 INDIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 77 INDIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 78 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 79 INDIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 INDIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 81 INDIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 82 INDIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 83 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 84 INDIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 85 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 86 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 87 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 88 SOUTH KOREA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 89 SOUTH KOREA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH KOREA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH KOREA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 92 SOUTH KOREA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 93 SOUTH KOREA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH KOREA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 95 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 96 SOUTH KOREA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 SOUTH KOREA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 98 SOUTH KOREA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 99 SOUTH KOREA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 100 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 101 SOUTH KOREA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 102 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 103 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 104 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 105 GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 106 AUSTRALIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 107 AUSTRALIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 108 AUSTRALIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 109 AUSTRALIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 110 AUSTRALIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 111 AUSTRALIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 112 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 113 AUSTRALIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 AUSTRALIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 115 AUSTRALIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 116 AUSTRALIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 117 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 118 AUSTRALIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 119 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 120 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 121 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 122 SINGAPORE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 123 SINGAPORE CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 124 SINGAPORE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 125 SINGAPORE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 126 SINGAPORE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 127 SINGAPORE HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 128 SINGAPORE RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 129 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 130 SINGAPORE HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 SINGAPORE WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 132 SINGAPORE VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 133 SINGAPORE POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 134 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 135 SINGAPORE POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 136 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 137 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 138 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 139 MALAYSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 140 MALAYSIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 141 MALAYSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 142 MALAYSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 143 MALAYSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 144 MALAYSIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 145 MALAYSIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 146 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 147 MALAYSIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 MALAYSIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 149 MALAYSIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 150 MALAYSIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 151 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 152 MALAYSIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 153 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 154 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 155 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 156 THAILAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 157 THAILAND CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 158 THAILAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 159 THAILAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 160 THAILAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 161 THAILAND HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 162 THAILAND RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 163 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 164 THAILAND HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 165 THAILAND WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 166 THAILAND VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 167 THAILAND POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 168 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 169 THAILAND POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 170 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 171 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 172 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 173 INDONESIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 174 INDONESIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 175 INDONESIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 176 INDONESIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 177 INDONESIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 178 INDONESIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 179 INDONESIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 180 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 181 INDONESIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 NDONESIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 183 INDONESIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 184 INDONESIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 185 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 186 INDONESIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 187 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 188 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 189 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 190 PHILIPPINES GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 191 PHILIPPINES CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 192 PHILIPPINES INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 193 PHILIPPINES PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 194 PHILIPPINES CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 195 PHILIPPINES HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 196 PHILIPPINES RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 197 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 198 PHILIPPINES HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 PHILIPPINES WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 200 PHILIPPINES VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 201 PHILIPPINES POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 202 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 203 PHILIPPINES POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 204 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 205 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 206 REST OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
Список рисунков
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CHRONIC DISEASES AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE ASIA-PACIFIC POINT-OF-CARE (POCT) TESTING MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC POINT-OFCARE (POCT) TESTING MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
FIGURE 14 EPIDEMIOLOGY OF CHRONIC CONDITIONS (1990-2015)
FIGURE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019
FIGURE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 20 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 24 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019
FIGURE 28 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019
FIGURE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE (2020-2027)
FIGURE 48 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET: COMPANY SHARE 2019 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.